Risankizumab for 12 Weeks Leads to Remission in Crohn’s Trials
Crohn's Disease, News
Treatment with risankizumab for 12 weeks (three months) induced both clinical and endoscopic remission in people with Crohn’s disease, a type of inflammatory bowel disease (IBD), new Phase 3 clinical ... Read more